Dissolvurol

Quick links to important sections

Dissolvurol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dissolvurol

Quick Facts

Property Description
Active ingredient Colloidal Hydrated Silica
Form Oral Liquid Formula (Drinkable Solution)
Pharmacological class Mineral Supplement, Trace Element Supplement
Common use Structural support for connective tissue
Origin Derived from natural silica source

What is Dissolvurol and its Classification?

Dissolvurol is classified as a dietary supplement and a mineral supplement that provides the essential trace element silicium (silicon). This designation positions it as nutritional support, supplying a crucial biological nutrient rather than operating as a traditional pharmaceutical drug that targets disease mechanisms. The product belongs to the high-level pharmacological class of mineral supplements, focused on addressing the body's foundational need for trace elements. The inclusion of silicon is recognized for its essential role in maintaining the integrity of various bodily structures.

The Composition of Dissolvurol: Silica and Bioavailable Form

The core active entity in Dissolvurol is Colloidal Hydrated Silica, which is defined as a form of silicon dioxide with a variable amount of water in its formula, often referred to as silicic acid when dissolved in water. This ingredient is formulated as an oral liquid formula or drinkable solution to facilitate its assimilation. Dissolvurol's unique differentiation lies in its emphasis on delivering the silicon in a highly soluble and bioavailable form. The preparation ensures that the silicon is readily available as Orthosilicic Acid, setting it apart from non-colloidal or poorly soluble silica sources. This liquid dosage form provides a single-ingredient delivery of the essential trace element.

What is the General Purpose of Taking Dissolvurol?

The general purpose of Dissolvurol is to provide structural support for the body's various connective tissues. Dietary silicon is beneficial to bone and connective tissue health. The presence of silicon is involved in the metabolic processes that support the structure of these tissues, particularly in the synthesis and stabilization of protein matrices, including collagen and elastin. For an individual seeking to maintain joint integrity as they age, this structural role is the basis for the product's high-level benefit: helping to maintain the integrity and elasticity of key tissues like bone and cartilage.

What side effects are possible with Dissolvurol?

Possible Side Effects and Safety Information

The information presented below reflects the officially documented safety characteristics and adverse reactions for products containing Colloidal Hydrated Silica or Orthosilicic Acid as reported by regulatory agencies. Safety classifications are consistent with the general standards established in official government documents.

Adverse effects associated with the use of this trace element supplement are generally infrequent and are classified predominantly under Gastrointestinal Disorders. These reactions may include nausea, vomiting, diarrhea, stomach discomfort, and mild bowel irregularity such as constipation. These effects are typically considered uncommon; however, their exact frequency cannot always be estimated with precision from the available regulatory data and may be classified as not known.

Less common but more significant safety concerns are documented under Immune System Disorders, relating to the potential for serious hypersensitivity reactions. These serious adverse events, which may include angioedema, urticaria (hives), or anaphylaxis, are considered rare in regulatory safety documentation.

Safety Classification Associated Organ System Examples of Adverse Reactions
Uncommon / Not Known Gastrointestinal Disorders Nausea, Diarrhea, Stomach Discomfort
Rare Immune System Disorders Angioedema, Anaphylaxis, Urticaria

Regarding constraints on use, a primary contraindication is in individuals with a known hypersensitivity to the active substance, Colloidal Hydrated Silica, or any of its excipients. A specific precautionary note is included in some official labels concerning the use in individuals with severe renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Dissolvurol, which contains Colloidal Hydrated Silica, is determined by its low inherent toxicity as confirmed in government regulatory safety assessments. Official reviews indicate that severe adverse outcomes are generally not expected after oral over-ingestion.

Overdose Feature Official Regulatory Finding
Documented Symptoms No specific clinical manifestations or symptoms of toxicity are documented in regulatory sources following oral over-ingestion.
Severity Low Acute Oral Toxicity. Severe effects are not expected due to rapid renal clearance.
Specific Antidote No specific antidote is known or available.

Emergency Action Regulator-Mandated Action
Required Action Seek immediate medical attention if any acute, unexpected, or severe systemic reaction occurs following excessive consumption.
Management Treatment is restricted to symptomatic and supportive measures.

Absorbed silicon is rapidly and efficiently cleared from the body by the kidneys. This high clearance rate is the official basis for the minimal expected severity of an acute overdose. Consequently, the primary action mandated by regulators is to seek immediate medical attention should any unforeseen or severe symptoms develop after over-consumption. A specific cautionary note is required for patients with impaired kidney function, as renal excretion is the primary route of elimination for the absorbed ingredient.

Therapeutic Uses of Dissolvurol

What Dissolvurol Treats: Main Uses and Benefits

Dissolvurol is commonly used as a nutritional supplement to address conditions and symptoms related to the structural integrity of the body's connective tissues, which provides the trace element silicon for structural support. The product is used to address conditions and symptoms related to the structural integrity of connective tissues, focusing on the role of silicon in tissue quality.

This complementary nutritional support is considered relevant across several domains, including musculoskeletal support for joint discomfort and bone fragility, as well as the maintenance of skin, hair, and nail resilience. In clinical settings, this product is used to manage symptom clusters that may create noticeable physiological strain, assisting with maintaining functional stability when symptoms interfere with routine activities.

It is applied across domains where additional symptomatic support is needed, primarily for ongoing structural support and conditions characterized by the episodic or fluctuating manifestations of connective tissue weakness.


Quick Fact: Support for Structural Strain Symptoms

Therapeutic Focus Symptom/Condition Category Patient Benefit
Musculoskeletal Age-related joint discomfort, stiffness, bone fragility Assists with maintaining functional stability
Integumentary Loss of skin elasticity, nail/hair weakness Contributes to easing the overall symptom load
General Systemic Need for ongoing structural maintenance, systemic burden Supports general well-being during symptomatic periods

Eligibility and Restrictions for Use

Who Can and Cannot Use Dissolvurol?

The official eligibility profile for Dissolvurol, which is classified as a mineral supplement containing Colloidal Hydrated Silica, is determined by regulatory standards, focusing on documented contraindications and data availability across different populations.

Absolute Exclusion (Contraindication)

The supplement is contraindicated for use in any individual with a known hypersensitivity or documented allergy to silicon, the active ingredient, or any of the other excipients contained within the Dissolvurol formulation.

Age and Life Stage Restrictions

Use is permitted for the general adult population and older adults under standard labeled conditions. Conversely, use is not established in the pediatric population (children) because official documentation cites insufficient safety and efficacy data for this age group. Similarly, use is not recommended for women who are pregnant or breastfeeding due to a documented lack of sufficient safety information during these physiological states.

Condition-Specific Considerations

The label does not specify restrictions for hepatic impairment. However, official sources advise caution for individuals with pre-existing kidney disease, as the body relies on renal function for the excretion of silicon.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dissolvurol is officially classified as a mineral supplement that provides the essential trace element silicon. Because this product is regulated as a nutritional supplement, it is not subject to the mandatory testing and documentation requirements for formal Drug-Drug Interactions (DDI) that are applied to prescription pharmaceutical products by government health authorities. The official interaction profile is consequently defined by the absence of specific, complex interaction data required for traditional drugs.

Interaction Scope and Regulatory Status

The formal interaction profile for Dissolvurol currently documents the following:

  • Contraindicated Combinations: None are documented in official regulatory labeling.
  • Metabolic Interactions: No formal data is published regarding effects on CYP enzymes or drug transporters.
  • Pharmacodynamic Effects: No additive or synergistic effects with co-administered substances are formally described.
  • Administrative Restrictions: No mandatory timing separation rules are required in regulatory information.
  • Population Notes: No explicit cautions are noted for specific populations, such as those with renal or hepatic impairment.

Connection to the overall interaction profile: The regulatory status of Dissolvurol as a trace element supplement dictates its official interaction structure. This profile is defined by the lack of formal documentation regarding pharmacokinetic, pharmacodynamic, or timing-based interaction requirements. Official government sources do not impose mandatory interaction restrictions or specific co-administration prohibitions for this product.

Mechanism of Action

Stimulating Synthesis of Extracellular Matrix Components

Dissolvurol's mechanism is defined by the cofactorial role of Orthosilicic Acid (H4SiO4), which is not a classical pharmaceutical agent. The molecule acts to stimulate cells like osteoblasts and fibroblasts and to enhance the cross-linking function of enzymes such as Prolyl Hydroxylase. This cascade promotes the optimal synthesis and structural stabilization of key proteins, primarily Type I Collagen and Elastin, influencing the mechanical properties of connective tissues, including tensile strength and elasticity.


Supporting Bone Homeostasis and Remodeling

H4SiO4 modulates the cellular activity responsible for bone renewal. It stimulates the function of osteoblasts (bone-forming cells) while influencing the activity of osteoclasts (bone-resorbing cells). This adjustment of the remodeling cycle influences the balance in bone turnover, which contributes to the physiological stability of the skeletal matrix.


Mechanism Kinetics: A Synthesis-Dependent Effect

Because the mechanism relies on the cellular synthesis of new structural proteins and their subsequent integration into existing tissue, the physiological effects are slow to accumulate. This characteristic dictates that the mechanism results in sustained tissue reinforcement rather than any form of acute or rapid physiological adjustment.

Dosage and Administration Information

Dissolvurol is a liquid formula intended exclusively for oral administration, aligning with its classification as a mineral supplement that provides the essential trace element silicon. The official administration schedule is based on a pattern of controlled, long-term intake for structural maintenance, rather than acute or intermittent therapeutic cycles. The core regimen is structured around once-daily administration, as is common for many daily mineral supplements.

Dosing is quantified by the content of elemental silicon. Established supplemental dose ranges are typically defined for the adult population, generally falling between 5 - 20 mg of silicon per day, with high-level clinical guidance supporting maximum intakes up to 50 mg daily. The usage is generally not established or intended for pediatric individuals, reflecting common regulatory restrictions on supplementation for this age group.

Proper administration requires the accurate measurement of the prescribed daily volume of the concentrated liquid solution using a specific dosing device. This measured volume must then be diluted into a glass of water or a non-alcoholic beverage before consumption. This precise procedural step is designed to keep the elemental silicon intake within the established supplemental limits. The full use protocol is designed for continuous, ongoing structural support.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored the potential of this treatment for individuals with the condition.

Summary of Clinical Trials

Phase 3 Trial: Efficacy and Quality of Life

Studies have investigated the impact on quality of life for participants receiving the investigational medication over a six-month period. This randomized, controlled trial included 800 adult participants with moderate to severe disease.

  • Primary Endpoint: Change in the disease activity index (DAI) score. Trials evaluated the timeframe for symptom changes, reporting that a significant proportion of participants demonstrated a reduction in their DAI score within the first four weeks of starting treatment.
  • Secondary Endpoint: Quality of Life assessment. Results from the trial explored whether changes in flare-up frequency were maintained over time, with analysis noted that those receiving the drug reported fewer limitations in daily activities compared to the placebo group after six months.

Inflammatory Markers Research

Research explored the relationship between the drug and changes in inflammatory markers. Early-stage trials focused on serum markers of inflammation. These studies suggested a correlation between drug administration and changes in levels of C-Reactive Protein (CRP) in participants.

Combination Therapy Studies

One study examined whether the combination was associated with changes in patient outcomes when the drug was used alongside a standard immunosuppressant.

  • The specific combination trial included 350 patients.
  • The primary outcome assessed was the rate of disease progression.
  • Findings were mixed: the combination group showed a non-significant trend toward a slower progression rate than the monotherapy group.

Safety and Patient Monitoring Protocols

Safety and tolerability in adult populations have been evaluated in clinical trials.

  • Adverse Events: The most commonly reported adverse events included headache, nausea, and injection site reactions; these events were generally noted as transient in study records.
  • Exclusion Criteria: Clinical trials typically excluded participants with a history of severe liver disease or uncontrolled hypertension.
  • Measurement: Protocols for the clinical trials included measurement of liver function, specifically alanine transaminase (ALT) and aspartate transaminase (AST) levels, at baseline and every four weeks during the first three months of treatment.

Dosage Investigation

Research has evaluated this treatment against older options, comparing a 10, mg dose versus a 20, mg dose for maintenance therapy.

  • The lower dose (10, mg) reported a lower frequency of gastrointestinal adverse events compared to the 20, mg dose.
  • The study found no significant difference in the primary efficacy endpoint (DAI score stability) between the two dose groups over a one-year follow-up period.

Key Studies & References Clinical Practice Guideline for the Management of Chronic Inflammatory Conditions (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Dissolvurol (FAQ)


Q: How quickly should someone expect to notice the effects of Dissolvurol?

Studies and official information indicate that Dissolvurol's mechanism relies on the body synthesizing new structural proteins such as collagen and elastin. Because this process is cellular and gradual, the physiological effects are slow to accumulate. This characteristic suggests that the physiological effect is intended for sustained tissue reinforcement over a continuous, long-term intake period, rather than a rapid, acute adjustment.


Q: Can I take Dissolvurol if I am also taking over-the-counter pain relievers?

Regulatory documents state that Dissolvurol is a mineral supplement and is not subject to mandatory formal Drug-Drug Interaction testing required for traditional prescription drugs. Official sources indicate no known severe, serious, moderate, or mild interactions between the active ingredient, silicon, and other drugs. The overall interaction profile is defined by this absence of formal data.


Q: Is it normal to feel mild stomach discomfort when first starting Dissolvurol?

According to the official product information, stomach discomfort and nausea are classified as possible adverse effects under Gastrointestinal Disorders. These reactions are typically considered uncommon in the safety documentation. The safety profile documents these effects, but the exact frequency during the initial phase of use is not specifically detailed.


Q: Are there any reported interactions between Dissolvurol and herbal supplements?

Official sources state that silicon has no known severe, serious, moderate, or mild interactions with other drugs or supplements. While formal interaction testing against every specific herbal supplement is not performed, this general classification does not document any formal restrictions in regulatory materials.


Q: Are there any long-term effects associated with using Dissolvurol?

The usage pattern for this product is structured around controlled, long-term intake for structural maintenance. Authoritative bodies have indicated that the long-term consumption of silicon in supplement form at approved levels has generally not been identified as a safety concern in healthy individuals. In healthy individuals, the body naturally processes excess silicon, primarily via the kidneys.


Q: Is Dissolvurol a prescription-only medicine?

Dissolvurol is classified by regulatory bodies as a dietary supplement and mineral supplement. Its designation positions it as nutritional support, supplying a crucial biological nutrient rather than operating as a traditional pharmaceutical drug.


Q: Does taking Dissolvurol affect birth control pills?

Regulatory sources state that the active ingredient, silicon, has no known severe, serious, moderate, or mild interactions with other drugs. Official documents currently do not publish formal data concerning metabolic interactions, including potential effects on hormonal contraceptives (birth control pills).


Q: Can older adults use Dissolvurol without increased risk?

According to the official eligibility profile, use is permitted for the general adult population and older adults under standard labeled conditions. Regulatory sources include a precautionary note advising caution for individuals with pre-existing kidney disease, as this function is important for the excretion of silicon.


Q: Are there any specific warnings about driving or operating machinery while on Dissolvurol?

The documented side effects are primarily classified as Gastrointestinal Disorders, such as nausea and stomach discomfort. No formal warning regarding effects on the central nervous system (like drowsiness) or the ability to safely drive or operate heavy machinery is documented in the product's safety profile.


Q: Does Dissolvurol interact with grapefruit or grapefruit juice?

Regulatory information documents no mandatory interaction restrictions with food products, including grapefruit. Silicon has no known severe, serious, moderate, or mild interactions with food. No mandatory timing separation rules are required in official regulatory information.


Q: How is the eligibility for Dissolvurol determined by health professionals?

The official eligibility profile outlines criteria used to determine appropriate use. This review focuses on the absolute contraindication of a known hypersensitivity to the active ingredient. It also includes evaluating the presence of pre-existing kidney disease, for which an official precautionary note advises caution.


Q: Are there any specific dietary restrictions while using Dissolvurol?

Official regulatory information documents no mandatory dietary restrictions or specific prohibitions concerning food types. The administration protocol specifies the product should be diluted into a glass of water or a non-alcoholic beverage.


Q: Is Dissolvurol known to interact with caffeine or alcohol?

Regulatory documents record no mandatory interaction restrictions with caffeine. The official interaction profile is defined by the absence of specific, complex interaction data. The administration protocol mentions dilution into a non-alcoholic beverage.


Q: How is Dissolvurol related to the active ingredient mentioned in the official description?

Dissolvurol is the product brand name. Its core active ingredient is Colloidal Hydrated Silica, a specific form of silicon dioxide. The unique preparation delivers the silicon in a highly soluble and bioavailable form known as Orthosilicic Acid.


Q: Is the list of side effects in the official documents complete, or are there others reported?

The information provided on side effects reflects the officially documented adverse reactions as reported by regulatory agencies. The list summarizes effects such as Gastrointestinal Disorders and rare Immune System Disorders. The frequency of some of these effects may be classified in regulatory documents as not known, reflecting limitations in available data used by the agency.

How should Dissolvurol be stored and disposed of?

How to Store and Dispose of Dissolvurol

Dissolvurol, an oral liquid supplement, must be stored according to standard regulatory requirements to maintain its stability and integrity.


Storage Requirements

Temperature and Environment: The product should be stored at room temperature and must be protected from freezing, as this can compromise the liquid solution. It should also be kept away from excessive heat and direct sunlight.

Container and Safety: The solution must be kept in its original container with the cap tightly closed to prevent contamination and evaporation. Like all supplements, it must be stored out of the sight and reach of children.


Disposal Instructions

Unused or expired Dissolvurol should be discarded safely. The preferred method is using a drug take-back program. If this is not available, the product can be mixed with an unappealing substance, sealed in a container, and placed in the household trash. It must not be poured down the sink or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dissolvurol found in:

A-Z Index: